Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Bemnifosbuvir and Ruzasvir in Chronic Hepatitis C Virus Infection
2023-504566-28-00Phase 2Completed
- Sponsor
- Atea Pharmaceuticals Inc.
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 2, open-label, single-arm trial of bemnifosbuvir and ruzavir in chronic hepatitis C (CHC), sponsored by Atea Pharmaceuticals Inc. Primary endpoint: SVR12. Started Jul 2023; status: completed.
02
Drugs
bemnifosbuvirruzavir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2023-504566-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504566-28-00.